Msaouel Pavlos, Lee Juhee, Karam Jose A, Thall Peter F
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2022 Aug 14;14(16):3923. doi: 10.3390/cancers14163923.
We discuss how causal diagrams can be used by clinicians to make better individualized treatment decisions. Causal diagrams can distinguish between settings where clinical decisions can rely on a conventional additive regression model fit to data from a historical randomized clinical trial (RCT) to estimate treatment effects and settings where a different approach is needed. This may be because a new patient does not meet the RCT's entry criteria, or a treatment's effect is modified by biomarkers or other variables that act as mediators between treatment and outcome. In some settings, the problem can be addressed simply by including treatment-covariate interaction terms in the statistical regression model used to analyze the RCT dataset. However, if the RCT entry criteria exclude a new patient seen in the clinic, it may be necessary to combine the RCT data with external data from other RCTs, single-arm trials, or preclinical experiments evaluating biological treatment effects. For example, external data may show that treatment effects differ between histological subgroups not recorded in an RCT. A causal diagram may be used to decide whether external observational or experimental data should be obtained and combined with RCT data to compute statistical estimates for making individualized treatment decisions. We use adjuvant treatment of renal cell carcinoma as our motivating example to illustrate how to construct causal diagrams and apply them to guide clinical decisions.
我们讨论了临床医生如何使用因果图来做出更好的个性化治疗决策。因果图可以区分以下两种情况:一种是临床决策可以依赖于对历史随机临床试验(RCT)数据拟合的传统加法回归模型来估计治疗效果;另一种是需要采用不同方法的情况。这可能是因为新患者不符合RCT的纳入标准,或者治疗效果会因生物标志物或其他在治疗与结局之间起中介作用的变量而改变。在某些情况下,只需在用于分析RCT数据集的统计回归模型中纳入治疗-协变量交互项,问题即可得到解决。然而,如果RCT纳入标准排除了临床中遇到的新患者,则可能需要将RCT数据与来自其他RCT、单臂试验或评估生物治疗效果的临床前实验的外部数据相结合。例如,外部数据可能显示RCT中未记录的组织学亚组之间治疗效果存在差异。因果图可用于决定是否应获取外部观察性或实验性数据,并将其与RCT数据相结合,以计算用于做出个性化治疗决策的统计估计值。我们以肾细胞癌的辅助治疗为例,来说明如何构建因果图并将其应用于指导临床决策。